Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Liabilities and Shareholders Equity: 2010-2024

Historic Liabilities and Shareholders Equity for Iovance Biotherapeutics (IOVA) over the last 10 years, with Dec 2024 value amounting to $910.4 million.

  • Iovance Biotherapeutics' Liabilities and Shareholders Equity was N/A to $904.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year change of. This contributed to the annual value of $910.4 million for FY2024, which is 16.67% up from last year.
  • As of FY2024, Iovance Biotherapeutics' Liabilities and Shareholders Equity stood at $910.4 million, which was up 16.67% from $780.4 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Liabilities and Shareholders Equity high stood at $910.4 million for FY2024, and its period low was $780.4 million during FY2023.
  • Moreover, its 2-year median value for Liabilities and Shareholders Equity was $845.4 million (2023), whereas its average is $845.4 million.
  • Data for Iovance Biotherapeutics' Liabilities and Shareholders Equity shows a peak YoY grew of 16.67% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Iovance Biotherapeutics' Liabilities and Shareholders Equity stood at $780.4 million in 2023, then grew by 16.67% to $910.4 million in 2024.